Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Medley: Phase 1b/2 study of avelumab in combination with other cancer immunotherapies in advanced malignancies
jRCT2080223163Phase 2Completed
- Start
- Apr 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of avelumab in Non-hematologic malignancy. Primary endpoints: Safety and tolerability, Clinical activity and 2 more. Started Apr 2016; status: completed.
02
Drugs
avelumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080223163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223163.